Century Therapeutics to Present at Upcoming Investor Conferences
February 21 2023 - 7:00AM
Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage
biotechnology company developing induced pluripotent stem cell
(iPSC)-derived cell therapies in immuno-oncology, today announced
that members of the management team will participate in the
following investor conferences:
- H.C. Wainwright Cell Therapy Virtual Conference. The fireside
chat will take place at 10:30 AM ET on Tuesday, February 28,
2023.
- Cowen 43rd Annual Health Care Conference. The presentation will
take place at 11:10 AM ET on Monday, March 6, 2023.
A replay of the events will be available on the
“Events & Presentations” page in the “Investors” section of the
Company’s website
at https://investors.centurytx.com/events-and-presentations
and will be available for 30 days following the events.
About Century Therapeutics
Century Therapeutics, Inc. (NASDAQ: IPSC) is a
clinical-stage biotechnology company harnessing the power of adult
stem cells to develop curative cell therapy products for cancer
that we believe will allow us to overcome the limitations of
first-generation cell therapies. Our genetically engineered,
iPSC-derived iNK and iT cell product candidates are designed to
specifically target hematologic and solid tumor cancers. We are
leveraging our expertise in cellular reprogramming, genetic
engineering, and manufacturing to develop therapies with the
potential to overcome many of the challenges inherent to cell
therapy and provide a significant advantage over existing cell
therapy technologies. We believe our commitment to developing
off-the-shelf cell therapies will expand patient access and provide
an unparalleled opportunity to advance the course of cancer care.
For more information on Century Therapeutics please visit
https://www.centurytx.com/.
Century Therapeutics Forward-Looking
Statement
This press release contains forward-looking
statements within the meaning of, and made pursuant to the safe
harbor provisions of, The Private Securities Litigation Reform Act
of 1995. All statements contained in this press release, other than
statements of historical facts or statements that relate to present
facts or current conditions, including but not limited to,
statements regarding our clinical development plans and timelines,
are forward-looking statements. These statements involve known and
unknown risks, uncertainties and other important factors that may
cause our actual results, performance, or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements. In some cases, you can identify forward-looking
statements by terms such as “may,” “might,” “will,” “should,”
“expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,”
“target,” “project,” “contemplate,” “believe,” “estimate,”
“predict,” “forecast,” “potential” or “continue” or the negative of
these terms or other similar expressions. The forward-looking
statements in this press release are only predictions. We have
based these forward-looking statements largely on our current
expectations and projections about future events and financial
trends that we believe may affect our business, financial
condition, and results of operations. These forward-looking
statements speak only as of the date of this press release and are
subject to a number of risks, uncertainties and assumptions, some
of which cannot be predicted or quantified and some of which are
beyond our control, including, among others: our ability to
successfully advance our current and future product candidates
through development activities, preclinical studies, and clinical
trials; our ability to obtain FDA acceptance for our future IND
submissions and commence clinical trials on expected timelines, or
at all; our reliance on the maintenance of certain key
collaborative relationships for the manufacturing and development
of our product candidates; the timing, scope and likelihood of
regulatory filings and approvals, including final regulatory
approval of our product candidates; the impact of the COVID-19
pandemic, geopolitical issues and inflation on our business and
operations, supply chain and labor force; the performance of third
parties in connection with the development of our product
candidates, including third parties conducting our future clinical
trials as well as third-party suppliers and manufacturers; our
ability to successfully commercialize our product candidates and
develop sales and marketing capabilities, if our product candidates
are approved; and our ability to maintain and successfully enforce
adequate intellectual property protection. These and other risks
and uncertainties are described more fully in the “Risk Factors”
section of our most recent filings with the Securities and Exchange
Commission and available at www.sec.gov. You should not rely on
these forward-looking statements as predictions of future events.
The events and circumstances reflected in our forward-looking
statements may not be achieved or occur, and actual results could
differ materially from those projected in the forward-looking
statements. Moreover, we operate in a dynamic industry and economy.
New risk factors and uncertainties may emerge from time to time,
and it is not possible for management to predict all risk factors
and uncertainties that we may face. Except as required by
applicable law, we do not plan to publicly update or revise any
forward-looking statements contained herein, whether as a result of
any new information, future events, changed circumstances or
otherwise.
For More Information: Company:
Elizabeth Krutoholow – investor.relations@centurytx.comInvestors:
Melissa Forst/Maghan Meyers – century@argotpartners.comMedia:
Joshua R. Mansbach – century@argotpartners.com
Century Therapeutics (NASDAQ:IPSC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Century Therapeutics (NASDAQ:IPSC)
Historical Stock Chart
From Sep 2023 to Sep 2024